Salud financiera de hoja de balance de Aurinia Pharmaceuticals
Salud financiera controles de criterios 6/6
Aurinia Pharmaceuticals tiene un patrimonio de los accionistas total de $388.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $549.4M y $161.4M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$348.24m |
| Patrimonio | US$388.00m |
| Total pasivo | US$161.36m |
| Activos totales | US$549.36m |
Actualizaciones recientes sobre salud financiera
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Recent updates
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($440.5M) de AUPH superan a sus pasivos a corto plazo ($78.6M).
Pasivo a largo plazo: Los activos a corto plazo de AUPH ($440.5M) superan a sus pasivos a largo plazo ($82.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AUPH está libre de deudas.
Reducción de la deuda: AUPH no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable AUPH tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: AUPH no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 7.7% al año.